1-5 of 5
Shuo-Chieh Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia

Ce Shi, PhD, Lina Han, PhD, Qi Zhang, Kathryn G. Roberts, Eugene Park, Yoko Tabe, MD PhD, Rodrigo Omar Jacamo, PhD, Hong Mu, MD PhD, Shuo-Chieh Wu, Jin Zhou, Helen Ma, Zhihong Zeng, MD, Nitin Jain, MD, Elias J Jabbour, MD, Markus Muschen, MDPhD, Sarah K Tasian, MD, Charles G. Mullighan, MBBS, MSc, MD, David M. Weinstock, David Fruman, PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2529.
https://doi.org/10.1182/blood.V126.23.2529.2529
Published: 2015
Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Loretta S. Li, MD, Shuo-Chieh Wu, Nadja Kopp, MA, Joan Montero, PhD, Jeremy Ryan, SM, Bjoern Chapuy, MD PhD, Jordy C. Van der Zwet, Jacob Layer, Oliver Weigert, MD, Amanda L Christie, Alexandra N. Christodoulou, Huiyun Liu, Akinori Yoda, PhD, Francesco Hofmann, PhD, Fabienne Baffert, Eric Vangrevelinghe, Christoph Gaul, PhD, Thomas Radimerski, PhD, Anthony G. Letai, MD PhD, David M. Weinstock, MD
Journal: Blood
Blood (2014) 124 (21): 3713.
https://doi.org/10.1182/blood.V124.21.3713.3713
Published: 2014
Journal Articles

Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2 -Rearranged Ph-like Acute Lymphoblastic Leukemia

Ce Shi, Lina Han, PhD, Yoko Tabe, MD PhD, Hong Mu, MD PhD, Shuo-Chieh Wu, Jin Zhou, MD, PhD, Zhihong Zeng, MD, David A Fruman, PhD, Sarah K Tasian, MD, David M. Weinstock, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3706.
https://doi.org/10.1182/blood.V124.21.3706.3706
Published: 2014
Journal Articles

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

Akinori Yoda, PhD, Guillaume Adelmant, PhD, Jerome Tamburini, MD PhD, Bjoern Chapuy, MD PhD, Nobuaki Shindoh, PhD, Yuka Yoda, MPh, Oliver Weigert, MD, Nadja Kopp, MA, Shuo-Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Amanda L Christie, Kutlu G Elpek, Joseph Card, Kira Gritsman, MD PhD, Jason Gotlib, MD MS, Michael W. Deininger, Hideki Makishima, MD PhD, Shannon Turley, PhD, Nathalie Javidi-Sharifi, Jaroslaw P. Maciejewski, MD PhD, Scott J Rodig, MD PhD, Jeffrey W. Tyner, Jarrod A Marto, PhD, David M. Weinstock, MD, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3567.
https://doi.org/10.1182/blood.V124.21.3567.3567
Published: 2014
Journal Articles

The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies

Akinori Yoda, PhD, Guillaume Adelmant, PhD, Nobuaki Shindoh, PhD, Bjoern Chapuy, MD, PhD, Yuka Yoda, MPh, Oliver Weigert, Nadja Kopp, Shuo-Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Jeffrey W. Tyner, Jason Gotlib, MD, MS, Michael W. Deininger, MD, PhD, Shannon Turley, PhD, Jarrod A Marto, PhD, Andrew A. Lane, MD, PhD, David M. Weinstock, MD
Journal: Blood
Blood (2013) 122 (21): 2510.
https://doi.org/10.1182/blood.V122.21.2510.2510
Published: 2013